Advertisement

Advertisement

SABS Stock Latest News

SAB Biotherapeutics advances SAB-142 Type 1 diabetes trial

Company AnnouncementsSAB Biotherapeutics advances SAB-142 Type 1 diabetes trial

SAB Biotherapeutics initiated with an Overweight at Barclays

PremiumThe Fly

SAB Biotherapeutics initiated with an Overweight at Barclays

1M ago

SAB Biotherapeutics Shareholders Back Board and Auditor

PremiumCompany Announcements

SAB Biotherapeutics Shareholders Back Board and Auditor

1M ago

SAB Biotherapeutics Reaffirmed Buy/High Risk on Regulatory Derisking, Positive SAB-142 Data and Unchanged $11 Price Target

PremiumRatings

SAB Biotherapeutics Reaffirmed Buy/High Risk on Regulatory Derisking, Positive SAB-142 Data and Unchanged $11 Price Target

2M ago

SAB Biotherapeutics: Buy Rating Reiterated as Tzield Approval De-Risks SAB-142, $10 Price Target Maintained

PremiumRatings

SAB Biotherapeutics: Buy Rating Reiterated as Tzield Approval De-Risks SAB-142, $10 Price Target Maintained

2M ago

SAB Biotherapeutics initiated with a Buy at Citi

PremiumThe FlySAB Biotherapeutics initiated with a Buy at Citi

2M ago

SAB Biotherapeutics initiated with a Buy at Jefferies

The Fly

SAB Biotherapeutics initiated with a Buy at Jefferies

2M ago

SAB Biotherapeutics price target raised to $10 from $7 at H.C. Wainwright

The Fly

SAB Biotherapeutics price target raised to $10 from $7 at H.C. Wainwright

3M ago

SAB Biotherapeutics Signs Manufacturing Pact for SAB-142

PremiumCompany Announcements

SAB Biotherapeutics Signs Manufacturing Pact for SAB-142

3M ago

Emergent BioSolutions enters SAB-142 development pact with SAB Biotherapeutics

PremiumThe Fly

Emergent BioSolutions enters SAB-142 development pact with SAB Biotherapeutics

3M ago

Buy Rating on SABS Driven by SAB-142’s Differentiated T1D Mechanism, Durable C‑Peptide Preservation, and Pivotal SAFEGUARD Catalyst

PremiumRatings

Buy Rating on SABS Driven by SAB-142’s Differentiated T1D Mechanism, Durable C‑Peptide Preservation, and Pivotal SAFEGUARD Catalyst

3M ago

SAB Biotherapeutics Highlights Positive Phase 1 SAB-142 Results

PremiumCompany Announcements

SAB Biotherapeutics Highlights Positive Phase 1 SAB-142 Results

3M ago

SAB Biotherapeutics initiated with a Buy at Rodman & Renshaw

PremiumThe FlySAB Biotherapeutics initiated with a Buy at Rodman & Renshaw

4M ago

SABS Upcoming Earnings Report: What to Expect?

Pre-Earnings

SABS Upcoming Earnings Report: What to Expect?

4M ago

SAB Biotherapeutics Launches Major Equity Financing Offering

Company Announcements

SAB Biotherapeutics Launches Major Equity Financing Offering

5M ago

SAB Biotherapeutics 19.325M share Spot Secondary priced at $3.85

PremiumThe Fly

SAB Biotherapeutics 19.325M share Spot Secondary priced at $3.85

5M ago

SAB Biotherapeutics $75M Spot Secondary; price range $3.75-$4.07

PremiumThe Fly

SAB Biotherapeutics $75M Spot Secondary; price range $3.75-$4.07

5M ago

SAB Biotherapeutics announces common stock offering, no amount given

PremiumThe Fly

SAB Biotherapeutics announces common stock offering, no amount given

5M ago

SAB Biotherapeutics price target raised to $14 from $12 at Chardan

PremiumThe Fly

SAB Biotherapeutics price target raised to $14 from $12 at Chardan

5M ago

SAB Biotherapeutics Highlights New Phase 1 SAB-142 Data

PremiumCompany AnnouncementsSAB Biotherapeutics Highlights New Phase 1 SAB-142 Data

5M ago

SAB Biotherapeutics announces additional Phase 1 data for SAB-142

The Fly

SAB Biotherapeutics announces additional Phase 1 data for SAB-142

5M ago

Analysts Predict Up to 400% Spike for These 2 ‘Strong Buy’ Penny Stocks

Stock Analysis & Ideas

Analysts Predict Up to 400% Spike for These 2 ‘Strong Buy’ Penny Stocks

6M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >